Skip to main content
×
Home
    • Aa
    • Aa

Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: A Systematic Review and Meta-analysis

  • Luis Furuya-Kanamori (a1), Jennifer C. Stone (a2), Justin Clark (a3), Samantha J. McKenzie (a2), Laith Yakob (a4), David L. Paterson (a5), Thomas V. Riley (a6), Suhail A. R. Doi (a2) and Archie C. Clements (a1)...
Abstract
Background

Clostridium difficile infection (CDI) has been extensively described in healthcare settings; however, risk factors associated with community-acquired (CA) CDI remain uncertain. This study aimed to synthesize the current evidence for an association between commonly prescribed medications and comorbidities with CA-CDI.

Methods

A systematic search was conducted in 5 electronic databases for epidemiologic studies that examined the association between the presence of comorbidities and exposure to medications with the risk of CA-CDI. Pooled odds ratios were estimated using 3 meta-analytic methods. Subgroup analyses by location of studies and by life stages were conducted.

Results

Twelve publications (n=56,776 patients) met inclusion criteria. Antimicrobial (odds ratio, 6.18; 95% CI, 3.80–10.04) and corticosteroid (1.81; 1.15–2.84) exposure were associated with increased risk of CA-CDI. Among the comorbidities, inflammatory bowel disease (odds ratio, 3.72; 95% CI, 1.52–9.12), renal failure (2.64; 1.23–5.68), hematologic cancer (1.75; 1.02–5.68), and diabetes mellitus (1.15; 1.05–1.27) were associated with CA-CDI. By location, antimicrobial exposure was associated with a higher risk of CA-CDI in the United States, whereas proton-pump inhibitor exposure was associated with a higher risk in Europe. By life stages, the risk of CA-CDI associated with antimicrobial exposure greatly increased in adults older than 65 years.

Conclusions

Antimicrobial exposure was the strongest risk factor associated with CA-CDI. Further studies are required to investigate the risk of CA-CDI associated with medications commonly prescribed in the community. Patients with diarrhea who have inflammatory bowel disease, renal failure, hematologic cancer, or diabetes are appropriate populations for interventional studies of screening.

Infect Control Hosp Epidemiol 2014;00(0):1–10

Copyright
Corresponding author
Address correspondence to Luis Furuya-Kanamori, MEpi, Research School of Population Health, Australian National University, Canberra, ACT 2601, Australia (Luis.Furuya-Kanamori@anu.edu.au).
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2. JL Kuntz , EA Chrischilles , JF Pendergast , LA Herwaldt , PM Polgreen . Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC Infect Dis 2011;11:194.

3. A Deshpande , P Pasupuleti , P Thota , et al. Community-associated Clostridium difficile infection antibiotics: a meta-analysis. J Antimicrob Chemother 2013;68:19511961.

7. S Janarthanan , I Ditah , DG Adler , MN Ehrinpreis . Clostridium difficile–associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012;107:10011010.

8. IM Tleyjeh , AB Abdulhak , M Riaz , et al. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLOS One 2013;8:e56498.

9. IM Tleyjeh , AA Bin Abdulhak , M Riaz , et al. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic review and meta-analysis. PLOS One 2012;7:e50836.

11. S Shukla , A Shukla , S Guha , S Mehboob . Use of proton pump inhibitors and risk of Clostridium difficile–associated diarrhea: a meta-analysis. Gastroenterology 2010;138:S209.

12. JR Goodhand , W Alazawi , D Rampton . Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:428441.

14. JS Bajaj , JG O'Leary , KR Reddy , et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American Consortium for the Study of End-Stage Liver Disease (NACSELD) experience. Hepatology 2012;56:23282335.

15. S Waffenschmidt , T Janzen , E Hausner , T Kaiser . Simple search techniques in PubMed are potentially suitable for evaluating the completeness of systematic reviews. J Clin Epidemiol 2013;66:660665.

16. R DerSimonian , N Laird . Meta-analysis in clinical trials. Control Clin Trials 1986;7:177188.

17. S Senn . Trying to be precise about vagueness. Stat Med 2007;26:14171430.

19. C Poole , S Greenland . Random-effects meta-analyses are not always conservative. Am J Epidemiol 1999;150:469475.

20. SA Doi , L Thalib . A quality-effects model for meta-analysis. Epidemiology 2008;19:94100.

23. AA Onitilo , SAR Doi , JJ Barendregt . Meta-analysis II: interpretation and use of outputs. In Doi SAR, Williams GM, eds. Methods of Clinical Epidemiology. Berlin: Springer Berlin Heidelberg, 2013:253266.

24. JAC Sterne , AJ Sutton , JPA Ioannidis , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.

25. S Dial , JA Delaney , AN Barkun , S Suissa . Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile–associated disease. JAMA 2005;294:29892995.

27. S Dial , JA Delaney , V Schneider , S Suissa . Proton pump inhibitor use and risk of community-acquired Clostridium difficile–associated disease defined by prescription for oral vancomycin therapy. Can Med Assoc J 2006;175:745748.

29. LM Soes , HM Holt , B Bottiger , et al. The incidence and clinical symptomatology of Clostridium difficile infections in a community setting in a cohort of Danish patients attending general practice. Euro J Clin Microbiol 2014;33:957967.

31. CA Marwick , N Yu , MC Lockhart , et al. Community-associated Clostridium difficile infection among older people in Tayside, Scotland, is associated with antibiotic exposure and care home residence: cohort study with nested case-control. J Antimicrob Chemother 2013;68:29272933.

32. DO Lowe , MM Mamdani , A Kopp , DE Low , DN Juurlink . Proton pump inhibitors and hospitalization for Clostridium difficile–associated disease: a population-based study. Clin Infect Dis 2006;43:12721276.

34. S Johnson , DN Gerding . Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:10271034.

35. RL Jump , MJ Pultz , CJ Donskey . Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile–associated diarrhea? Antimicrob Agents Chemother 2007;51:28832887.

36. S Hernández-Díaz , LAG Rodríguez . Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001;153:10891093.

37. DM Patrick , F Marra , J Hutchinson , DL Monnet , H Ng , WR Bowie . Per capita antibiotic consumption: how does a North American jurisdiction compare with Europe? Clin Infect Dis 2004;39:1117.

40. FC Lessa , CV Gould , LC McDonald . Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012;55:S65S70.

43. SE Brockwell , IR Gordon . A comparison of statistical methods for meta-analysis. Stat Med 2001;20:825840.

44. I Vesteinsdottir , S Gudlaugsdottir , R Einarsdottir , E Kalaitzakis , O Sigurdardottir , ES Bjornsson . Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case-control study. Eur J Clin Microbiol 2012;31:26012610.

47. S Naggie , BA Miller , KB Zuzak , et al. A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med 2011;124(276):e271e277.

48. D Suissa , JAC Delaney , S Dial , P Brassard . Non-steroidal anti-inflammatory drugs and the risk of Clostridium difficile–associated disease. Br J Clin Pharmacol 2012;74:370375.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Infection Control & Hospital Epidemiology
  • ISSN: 0899-823X
  • EISSN: 1559-6834
  • URL: /core/journals/infection-control-and-hospital-epidemiology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×
Type Description Title
WORD
Supplementary Materials

Furuya-Kanamori Supplementary Material
Appendices

 Word (722 KB)
722 KB

Metrics

Full text views

Total number of HTML views: 20
Total number of PDF views: 138 *
Loading metrics...

Abstract views

Total abstract views: 502 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 29th May 2017. This data will be updated every 24 hours.